Abstract
A series of N-biarylalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones were prepared and evaluated for biological activity at opioid (μ, δ, κ) and opioid receptor like-1 (ORL-1) G-protein coupled receptors. Substitution on the biaryl moiety produced enhanced affinity for the μ-opioid receptor.
Keywords: mu receptor, delta receptor, kappa receptor, nociceptin receptor, pain, 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, heteroarylphenylalkyl, sar, [35s]gtpγs binding assay, suzuki reaction
Medicinal Chemistry
Title: 8-(Heteroaryl)phenalkyl-1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as Opioid Receptor Modulators
Volume: 1 Issue: 6
Author(s): A. D. Jordan, M. J. Orsini, S. A. Middleton, P. J. Connolly, D. E. Brenneman, K. Pan and A. B. Reitz
Affiliation:
Keywords: mu receptor, delta receptor, kappa receptor, nociceptin receptor, pain, 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, heteroarylphenylalkyl, sar, [35s]gtpγs binding assay, suzuki reaction
Abstract: A series of N-biarylalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones were prepared and evaluated for biological activity at opioid (μ, δ, κ) and opioid receptor like-1 (ORL-1) G-protein coupled receptors. Substitution on the biaryl moiety produced enhanced affinity for the μ-opioid receptor.
Export Options
About this article
Cite this article as:
Jordan D. A., Orsini J. M., Middleton A. S., Connolly J. P., Brenneman E. D., Pan K. and Reitz B. A., 8-(Heteroaryl)phenalkyl-1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as Opioid Receptor Modulators, Medicinal Chemistry 2005; 1 (6) . https://dx.doi.org/10.2174/157340605774598207
DOI https://dx.doi.org/10.2174/157340605774598207 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Current Nanoscience The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Substance Use Disorder Related to Kratom (Mitragyna speciosa) Use in Malaysia
Current Psychopharmacology Capillary Electrophoresis–Mass Spectrometry in Metabolomics: The Potential for Driving Drug Discovery and Development
Current Drug Metabolism Entry of Oximes into the Brain: A Review
Current Medicinal Chemistry Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Hrd1 Facilitates Tau Degradation and Promotes Neuron Survival
Current Molecular Medicine From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry [<sup>18</sup>F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Current Alzheimer Research Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets
Current Pharmaceutical Design Plant Secondary Metabolites- Potent Inhibitors of Monoamine Oxidase Isoforms
Central Nervous System Agents in Medicinal Chemistry Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design The Impact of Omega-3 Fatty Acids on Osteoporosis
Current Pharmaceutical Design Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism